Restorative Dentistry Division, School of Dentistry, International Medical University Kuala Lumpur, Kuala Lumpur, Malaysia.
School of Pharmacy, International Medical University Kuala Lumpur, 126, Jalan Jalil Perkasa 19, Bukit Jalil, 57000, Wilayah Persekutuan Kuala Lumpur, Malaysia.
BMC Oral Health. 2024 Mar 25;24(1):382. doi: 10.1186/s12903-024-04069-0.
To analyze anti-MMP mode of action of Quaternary Ammonium Silane (QAS, codenamed as k21) by binding onto specific MMP site using computational molecular simulation and Anti-Sortase A (SrtA) mode of action by binding onto specific site using computational molecular simulation.
In silico Molecular Dynamics (MD) was used to determine the interactions of K21 inside the pocket of the targeted protein (crystal structure of fibroblast collagenase-1 complexed to a diphenyl-ether sulphone based hydroxamic acid; PDB ID: 966C; Crystal structure of MMP-2 active site mutant in complex with APP-derived decapeptide inhibitor. MD simulations were accomplished with the Desmond package in Schrödinger Drug Discovery Suite. Blood samples (~ 0.5 mL) collected into KEDTA were immediately transferred for further processing using the Litron MicroFlow® PLUS micronucleus analysis kit for mouse blood according to the manufacturer's instructions. Bacterial Reverse Mutation Test of K21 Molecule was performed to evaluate K21 and any possible metabolites for their potential to induce point mutations in amino acid-requiring strains of Escherichia coli (E. coli) (WP2 uvrA (tryptophan-deficient)).
Molecular Simulation depicted that K21 has a specific pocket binding on various MMPs and SrtA surfaces producing a classical clouting effect. K21 did not induce micronuclei, which are the result of chromosomal damage or damage to the mitotic apparatus, in the peripheral blood reticulocytes of male and female CD-1 mice when administered by oral gavage up to the maximum recommended dose of 2000 mg/kg. The test item, K21, was not mutagenic to Salmonella typhimurium (S. typhimurium) strains TA98, TA100, TA1535 and TA1537 and E. coli strain WP2 uvrA in the absence and presence of metabolic activation when tested up to the limit of cytotoxicity or solubility under the conditions of the test.
K21 could serve as a potent protease inhibitor maintaining the physical and biochemical properties of dental structures.
通过计算分子模拟分析季铵硅烷(QAS,代号为 k21)与特定 MMP 结合的抗 MMP 作用模式,以及通过计算分子模拟与特定位点结合的抗 Sortase A(SrtA)作用模式。
使用计算机分子动力学(MD)来确定 K21 在靶向蛋白口袋内的相互作用(纤维母细胞胶原酶-1 与二苯醚砜基羟肟酸复合物的晶体结构;PDB ID:966C;基质金属蛋白酶-2 活性位点突变体与 APP 衍生十肽抑制剂复合物的晶体结构。MD 模拟使用 Schrödinger Drug Discovery Suite 中的 Desmond 包完成。收集到含有 KEDTA 的血液样本(约 0.5 毫升),按照制造商的说明,立即转移到 Litron MicroFlow® PLUS 微核分析试剂盒中,用于小鼠血液的进一步处理。对 K21 分子进行细菌回复突变试验,以评估 K21 及其任何可能的代谢物是否有可能诱导大肠杆菌(E. coli)(WP2 uvrA(色氨酸缺陷))中氨基酸需求菌株的点突变。
分子模拟表明,K21 具有特定的口袋结合各种 MMP 和 SrtA 表面,产生典型的堵塞效应。当以口服灌胃方式给予雄性和雌性 CD-1 小鼠高达 2000mg/kg 的最大推荐剂量时,K21 不会在周围血网织红细胞中诱导微核,微核是染色体损伤或有丝分裂装置损伤的结果。在不存在和存在代谢激活的情况下,受试物 K21 对鼠伤寒沙门氏菌(S. typhimurium)菌株 TA98、TA100、TA1535 和 TA1537 以及 E. coli 菌株 WP2 uvrA 均无致突变性,在测试条件下达到细胞毒性或溶解度的极限。
K21 可作为一种有效的蛋白酶抑制剂,保持牙体结构的物理和生化特性。